[Hemophagocytic lymphohistiocytosis]

Rinsho Ketsueki. 2014 Feb;55(2):223-33.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antilymphocyte Serum / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Combined Modality Therapy
  • Cord Blood Stem Cell Transplantation
  • Cyclophosphamide / administration & dosage
  • Cyclosporine / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Drug Therapy, Combination
  • Etoposide / administration & dosage
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphohistiocytosis, Hemophagocytic / complications
  • Lymphohistiocytosis, Hemophagocytic / diagnosis
  • Lymphohistiocytosis, Hemophagocytic / physiopathology
  • Lymphohistiocytosis, Hemophagocytic / therapy*
  • Methotrexate / administration & dosage
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / prevention & control
  • Prednisolone / administration & dosage
  • Prednisone / administration & dosage
  • Rituximab
  • Severity of Illness Index
  • Transplantation Conditioning
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antilymphocyte Serum
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclosporine
  • Cyclophosphamide
  • Prednisolone
  • Vidarabine
  • fludarabine
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOP protocol